Give us a Call
+1 (915) 412-6680
Send us a Message
[email protected]
Opening Hours
Mon-Thu: 7 AM - 7 PM
Fri - Sun: Closed
Hormone Balance, Iron Health, and Contraceptive Care

Hormone Balance, Iron Health, and Contraceptive Care

Hormone Balance, Iron Health, and Contraceptive Care

Abstract

As a clinician blending chiropractic, functional medicine, and advanced nursing practice, I see how hormone physiology, micronutrients, and systems biology converge to shape health, recovery, and resilience. In this educational post, I walk you through practical, evidence-informed strategies for evaluating iron deficiency and ferritin; interpreting cortisol and thyroid dynamics; selecting and titrating progesterone, estrogen, and testosterone in complex scenarios (PCOS, IUD selection, male fertility and TRT rebound, TIA and stroke risk considerations, endometriosis, and menopause); and understanding the nuanced oncology context around DCIS and hormone receptors. I also explain how integrative chiropractic care fits into these plans by balancing the nervous and hormone systems, improving body functions, and supporting health through hands-on therapy, exercise, sleep, and diet. Throughout, I present current literature from leading researchers and add real-world observations from my practice (DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST) to help you translate physiology into precise, patient-centered care.

Foundations Of Identity In Care Planning And Clinical Context

  • Why this matters: Many patients navigate multiple identities—athlete and parent, caregiver and executive, patient and advocate. Clinically, multiple identities often map onto competing physiological stresses: sleep compression, high allostatic load, and variable patterns of nutrition and movement. Recognizing these factors is the first step in aligning care with lived realities.
  • Integrative chiropractic fit: In my clinic, identity-informed care plans build adherence. When I address spine and fascial mechanics and autonomic balance with targeted manual therapy, patients experience immediate relief that reinforces engagement with longer-term hormonal and nutritional strategies. Clinically, I see better follow-through on lab timing, supplement dosing, and structured movement when the body feels aligned and capable.

Iron Physiology, Ferritin, And Root-Cause Mapping

Understanding iron requires separating storage, transport, and utilization:

  • Key biomarkers:
    • Serum ferritin: a proxy for iron stores but an acute-phase reactant—elevates with inflammation (hepcidin-mediated sequestration).
    • Serum iron and transferrin/TIBC: reflect circulating iron and binding capacity.
    • Transferrin saturation (%): often the most useful single index with ferritin.
    • Reticulocyte hemoglobin (CHr) and soluble transferrin receptor (sTfR): help distinguish true deficiency from anemia of inflammation.

Physiology in brief:

  • The liver peptide hepcidin governs iron absorption and release from macrophages. Inflammation increases hepcidin, lowering absorption and locking iron in stores—low iron availability with normal/high ferritin.
  • True iron deficiency presents with low ferritin, low iron, high TIBC, and low transferrin saturation. Anemia of chronic inflammation shows low iron, low/normal TIBC, and normal/high ferritin.

Why patients stay iron-deficient:

  • Decreased intake or high phytate/polyphenol diets limit absorption.
  • Malabsorption: hypochlorhydria, celiac spectrum, SIBO, gastric bypass.
  • Losses: heavy menses, GI blood loss, frequent phlebotomy, and endurance training.
  • Special populations: neonates can experience early postnatal physiologic shifts; in adults, postpartum, post-surgery, and endurance athletes require tailored screening.

Clinical approach I use:

  • Map the cause: hydration status, GI absorption, occult bleeding (including fecal immunochemical testing), menstrual history, PPI use, celiac panel if indicated, and inflammatory markers (CRP, ESR).
  • Replace iron physiologically: I favor alternate-day oral iron to align with hepcidin’s diurnal rhythm and reduce GI side effects, supported by recent randomized trials showing improved absorption with every-other-day dosing (Stoffel et al., 2017). Using ferrous bisglycinate or heme iron polypeptide can enhance tolerance.
  • Repletion targets: Bring ferritin to symptom-relief thresholds (often 50–100 ng/mL for fatigue and hair loss), then sustain. Monitor hemoglobin, ferritin, and transferrin saturation every 8–12 weeks during repletion.

Integrative chiropractic fit:

  • Manual therapies that improve thoracic mobility and diaphragmatic excursion enhance vagal tone and GI perfusion, supporting absorption. Coaching on timing iron away from calcium and with vitamin C-rich foods further increases uptake. I often see faster symptom improvement when we combine postural breathing retraining and gentle aerobic conditioning with iron repletion.

Hormonal IUDs, Progestin Families, And Thrombotic Risk

Not all progestins are the same. Families differ in androgenicity and thrombotic risk:

  • Levonorgestrel (Mirena and similar): primarily a local uterine effect with low systemic levels; robust evidence supports low VTE risk compared with systemic progestins (ACOG, 2022).
  • Norethindrone: different side-effect profile and hepatic metabolism from progesterone; systemic exposure carries VTE risk similar to combined oral contraceptives when used in combination with estrogen.
  • Biologic progesterone (micronized) differs from synthetic progestins in receptor activity and in metabolites (e.g., allopregnanolone), which influence mood and sedation.

Why are Levonorgestrel IUDs often well tolerated?

  • The local endometrial action results in reduced systemic exposure, decreased bleeding, and endometrial protection, with a favorable safety profile. This is one reason neurosurgical and periprocedural contexts prefer local or targeted effects when feasible—namely, to reduce systemic adverse events.

Integrative chiropractic fit:

  • Pelvic floor integration matters. I routinely coordinate pelvic floor assessment and diaphragmatic mechanics with IUD choice. Improved lumbopelvic control and reduced sympathetic arousal can decrease cramping and improve IUD tolerance.

Progesterone Strategy In Sensitive Patients And PCOS Contexts

Clinical problem: Some patients with PCOS or HPA dysregulation report mood lability with oral progesterone.

Physiology:

  • Oral micronized progesterone converts to allopregnanolone, a positive allosteric modulator of GABA-A receptors. In most, this is anxiolytic; in a sensitive minority, neurosteroid fluctuations can provoke dysphoria.
  • Sublingual and transdermal routes bypass some first-pass metabolism, altering metabolite profiles and CNS effects.

My approach:

  • Start with a low-dose oral micronized progesterone (e.g., 100 mg qHS) to promote sleep and provide endometrial protection. If not tolerated:
    • Switch to a sublingual troche at half the equivalent oral dose (sublingual tends to achieve higher bioavailability; clinically, 100 mg sublingual can approximate 200 mg oral).
    • Quartering a 200 mg troche yields ~50 mg sublingual aliquots for fine titration.
  • Why this works: By modulating route and dose, we can smooth neurosteroid peaks, reduce daytime sedation, and maintain endometrial safety when used with estrogen.
  • For PCOS on androgen therapy: Balance is critical. A small androgen signal can be synergistic for mood, energy, and libido, but carefully calibrate it with estrogen and progesterone to avoid endometrial hyperplasia, acne, or dyslipidemia. Track SHBG, lipids, and insulin resistance.

Integrative chiropractic fit:

  • Autonomic stabilization through cervical-thoracic manipulation and breathing retraining reduces adrenergic drive that often amplifies progesterone sensitivity. When we address sleep quality and nocturnal bruxism with TMJ and cervical work, I see smoother adaptation to progesterone in practice.

Cortisol Testing: Salivary Profiles Versus Serum

Why measure multiple points:

  • Cortisol follows a diurnal curve: a peak within 30–45 minutes after waking (CAR) and a gradual decline throughout the day. A single AM serum cortisol measurement may miss dysregulated patterns.
  • A 4–5-point salivary cortisol series captures CAR, midday, afternoon, and evening levels—useful for sleep disturbances, burnout, and suspected HPA axis alterations (O’Connor et al., 2021).

When I choose each:

  • For pattern analysis and sleep complaints: multi-point salivary cortisol.
  • For adrenal insufficiency screening or acute illness: AM serum cortisol ± ACTH stimulation.

Integrative chiropractic fit:

  • Chiropractic care and breath-led movement can normalize autonomic balance, often flattening hyper-adrenergic spikes that correlate with evening cortisol elevations. I pair care with light-in-the-morning, dim-in-the-evening routines to reinforce circadian rhythms.

Male Fertility, Clomiphene, And TRT Rebound

In men in their 20s–30s with low testosterone who want fertility:

  • I avoid long-term estrogen receptor blockade. Short courses of clomiphene citrate (3–6 months) can increase LH/FSH levels, thereby increasing endogenous testosterone and sperm counts (Helo et al., 2017). It is not for indefinite use due to visual and mood risks and potential lipid changes.
  • Off peptides/TRT: I use timed clomiphene or enclomiphene to accelerate spermatogenesis while lifestyle and nutrition restore HPG axis tone.
  • Foundational first: For younger men, I prioritize diet quality, sleep, resistance training, weight normalization, and correcting micronutrient levels (vitamin D, B-complex, zinc, magnesium). I frequently see total testosterone rise from low 300s into 700–800 ng/dL over 6–9 months with lifestyle adherence.

Integrative chiropractic fit:

  • Restoring thoracic mobility and rib mechanics improves breathing efficiency and training capacity; correcting lumbopelvic mechanics reduces systemic inflammation from overuse. The autonomic shift toward parasympathetic tone deepens sleep, which is crucial for nocturnal gonadal hormone secretion.

DCIS, Hormone Receptors, And Personalized Risk-Benefit

Terminology and nuance:

  • Ductal carcinoma in situ (DCIS) is a noninvasive neoplastic process confined to the ducts. While often called “stage 0 breast cancer,” it lacks stromal invasion; management varies widely.
  • Receptor positivity (ER, PR, AR) indicates ligand-responsive pathways. Receptors are normal cellular features; their presence does not inherently mandate systemic suppression in all contexts.

Standard-of-care realities:

  • Many oncology pathways default to anti-estrogen strategies (e.g., tamoxifen) in receptor-positive lesions. My stance: align with oncology for invasive disease or recent treatment, but individualize for remote history or post-mastectomy scenarios, considering symptom burden and quality-of-life outcomes (Early Breast Cancer Trialists’ Collaborative Group, 2011; Cuzick et al., 2011).

Clinical reasoning:

  • In a patient decades post-bilateral mastectomy with no residual breast tissue, the theoretical tissue-specific risk is different from that of a patient 6 months post-lumpectomy still on adjuvant therapy. I weigh the systemic benefits of estrogen (bone, vasomotor stability, cognition, urogenital health) against realistic tissue risks, use shared decision-making, and document this via informed consent.

Integrative chiropractic fit:

  • Many of these patients struggle with pain, sleep disruption, and deconditioning. Postural restoration, scar mobility work, and gentle strengthening reduce sympathetic load, allowing lower-dose hormone regimens to achieve symptom control.

TIA, Stroke Risk, And Sex Hormones

Historical concern has linked estrogen to stroke risk, particularly in oral forms and in older trials with higher doses started late after menopause. The modern view:

  • Route matters: Transdermal estradiol has a more favorable thrombotic profile than oral estradiol because it bypasses first-pass hepatic effects on clotting factors (Canonico et al., 2016).
  • Testosterone does not require routine discontinuation after TIA in carefully selected women and men; the focus is on global vascular risk management (blood pressure, glycemic load, sleep apnea, hematocrit monitoring in men on TRT).
  • In patients who received pellet therapy near a TIA event, I evaluate vascular risks comprehensively. Anecdotally and mechanistically, sustained androgen levels do not necessarily precipitate cerebrovascular events; confounding factors (dehydration, arrhythmia, migraine with aura, hypercoagulable states) must be assessed.

Why integrative care helps:

  • Cervical and upper thoracic biomechanical dysfunction can aggravate headaches and sympathetic tone. By improving cervical proprioception, rib mechanics, and breathing patterns, I observe reduced migraine frequency and better control of blood pressure variability, which complements hormone prudence.

Immediate-Release Versus Extended-Release In Symptom Relief

In my practice, I often choose immediate-release formulations when seeking neurosensory benefits (e.g., anxiolysis, sleep initiation) from agents with CNS effects because:

  • Faster onset can more directly target symptom windows (e.g., bedtime).
  • It allows finer titration and identification of dose-response relationships.

When I choose extended-release:

  • For hormones or agents where steady state is crucial to avoid peaks/valleys, or when side effects are dose-peak-related. Personalization is key.

Endometriosis And Menopause: Progesterone Essentials

Key principles:

  • In menopausal women with a history of endometriosis on estrogen therapy, I favor co-prescribing progesterone even without a uterus. Rationale: ectopic endometrial implants may persist extrauterine and remain hormonally responsive. Progesterone has anti-proliferative effects on endometrial tissue and may reduce the risk of malignant transformation (Vercellini et al., 2014).

Testosterone and endometriosis:

  • Testosterone generally has neutral direct effects on endometriotic lesions; symptom modulation is more indirect (energy, libido, mood). I monitor acne, hair growth, and lipids.

Integrative chiropractic fit:

  • Pelvic and lumbosacral mechanics impact pelvic congestion and pain. Coordinated pelvic floor therapy, sacroiliac mobilization, and graded movement often reduce pain and allow lower estrogen doses with better function.

Thyroid Physiology: T4, Reverse T3, And Desiccated Thyroid

Why do some patients struggle with isolated levothyroxine?

  • T4 to T3 conversion is context-dependent: inflammation (IL-6), chronic stress (cortisol), and caloric restriction increase deiodinase 3, generating reverse T3 as a protective brake.
  • Bolus T4 dosing can, in sensitive patients, drive higher reverse T3 and leave tissues relatively hypothyroid despite normal TSH and free T4.

When I consider combination therapy:

  • If free T3 is low-normal with symptoms and reverse T3 is elevated, a trial of T3 addition or desiccated thyroid can be considered, monitoring HR, BP, and symptoms.
  • Desiccated thyroid includes T1/T2 in addition to T4/T3; while evidence is mixed, some patients report improved well-being (Hoang et al., 2013). The physiologic appeal is a more native ratio of iodothyronines.

Dosing logic:

  • Keep total T3 exposure rational (avoid overtreatment). Many patients do well at conservative desiccated doses (e.g., 60–120 mg with split dosing) or modest liothyronine add-on.
  • If reverse T3 is persistently high, look upstream: inflammation, gut dysbiosis, iron deficiency, sleep apnea, and medications. Raising the dose alone rarely fixes a conversion problem.

Integrative chiropractic fit:

  • By improving sleep quality and decreasing pain, we reduce cortisol and catecholamine tone that can impair peripheral conversion. I frequently pair thyroid adjustments with gut-directed nutrition, iron repletion, and aerobic conditioning to normalize deiodinase activity.

Estriol, Estradiol, And Skin Or Urogenital Targets

  • Estriol (E3) is a weaker estrogen with higher affinity for ER-beta, associated with urothelial and skin benefits and a theoretical reduced proliferative risk profile (Labrie et al., 2017).
  • On its own, estriol is often too weak for vasomotor symptoms; patients may continue to have hot flashes with estriol pellets or low-dose creams.
  • Bi-est combinations (estriol + estradiol) can increase serum estradiol; monitor for bleeding. For vulvovaginal atrophy, low-dose local estradiol or estriol is typically effective with minimal systemic absorption.

Integrative chiropractic fit:

  • Postural improvement, hip mobility, and pelvic floor coordination augment local tissue perfusion and sexual function. Patients often need lower topical doses when musculoskeletal contributors are addressed.

TRT In Men: Hematocrit, Estradiol, And Practical Monitoring

For men on testosterone injections who feel great but develop high hematocrit:

  • Tactics include dose and interval adjustments, switching to transdermal forms, therapeutic phlebotomy if indicated, and addressing sleep apnea, hydration, and iron stores.
  • I monitor hematocrit, estradiol, SHBG, PSA, lipids, and blood pressure. Aromatization to estradiol can be beneficial for bone and mood; I avoid reflexive overuse of aromatase inhibitors and instead optimize dose and lifestyle.

Integrative chiropractic fit:

  • Correcting thoracic outlet and rib mechanics can support breathing and reduce sleep apnea severity alongside weight loss—a key driver of safer TRT hematology.

Gut-First When Thyroid Therapy “Should Work” But Doesn’t

When free T3 is approaching the target (e.g., 4.0+ pg/mL), yet patients still feel unwell:

  • I reassess gut health: dysbiosis, SIBO, post-viral inflammation, food sensitivities. The gut-liver axis modulates thyroid hormone metabolism and immune cross-talk, particularly in Hashimoto’s.
  • I commonly see symptom breakthroughs after:
    • Eliminating trigger foods (gluten in celiac spectrum; individualized otherwise),
    • Repleting selenium, zinc, iron, vitamin D, B12, and magnesium, and
    • Restoring sleep and movement rhythm.

Integrative chiropractic fit:

  • Vagal stimulation through breathing and thoracic mobilization, coupled with graded walking and core stability, improves motility and lowers systemic inflammatory tone.

Clinical Vignettes And Observations From Practice

  • Ferritin plateaus despite oral iron: With alternating-day dosing with vitamin C, stopping concurrent calcium, checking for H. pylori and celiac markers, and adding diaphragmatic breathing drills for reflux, patients often see ferritin rise to 60–100 ng/mL within 12–16 weeks. Combining manual therapy to reduce costal margin restriction improved tolerance of iron and reduced GERD complaints in my clinic.
  • Progesterone intolerance in perimenopause: Switching from 200 mg oral nightly to 50–100 mg sublingual in divided evening doses, plus cervical release and sleep hygiene, stabilized mood and sleep within two cycles for most sensitive patients.
  • Young male with low T and fatigue: A 9-month plan emphasizing whole-food nutrition, vitamin D repletion to 40–60 ng/mL, magnesium glycinate at night, and progressive resistance training raised total testosterone from 320 ng/dL to 760 ng/dL without medications. Thoracic mobility and hip hinge training improved recovery and adherence.
  • Post-DCIS symptom burden: In a patient more than a decade post-bilateral mastectomy with severe vasomotor symptoms, a carefully titrated transdermal estradiol patch with nightly progesterone, plus scapular mobility and postural rehabilitation, improved sleep and cognition. Shared decision-making and documented informed consent were essential.

Why Integrative Chiropractic Care Amplifies Endocrine Therapies

  • Autonomic regulation: Pain and joint dysfunction heighten sympathetic tone, disrupting sleep, glucose metabolism, and thyroid hormone conversion. Manual therapy, spinal mobilization, and breathing retraining shift HRV toward parasympathetic balance, creating a biological environment in which hormones function as intended.
  • Movement economy: Efficient biomechanics reduce inflammatory signaling from microtrauma and improve insulin sensitivity, crucial for PCOS, TRT safety, and thyroid action.
  • Adherence and feedback loops: Rapid musculoskeletal relief builds trust and momentum, making it easier to sustain nutrition, sleep, and medication regimens. Clinically, I consistently see greater lab improvements when patients are engaged in both structured movement and manual care.

Practical Protocol Checklists

Iron and ferritin

  • Assess ferritin, iron, TIBC, transferrin saturation, CRP, ESR, CBC, retic Hb.
  • Identify cause: menses, GI loss, malabsorption, diet, PPI use.
  • Replace with alternate-day dosing; recheck at 8–12 weeks.
  • Add diaphragmatic breathing and gentle conditioning.

Progesterone strategies

  • Start 100–200 mg oral micronized qHS; if intolerant, consider 50–100 mg sublingual divided.
  • For estrogen users, ensure endometrial protection.
  • In the history of endometriosis, there is a continued use of estrogen and progesterone even post-hysterectomy.

Cortisol evaluation

  • Use 4–5-point salivary cortisol to assess diurnal rhythm; AM serum for insufficiency screening.
  • Implement light therapy, sleep hygiene, and autonomic-balancing manual care.

Male fertility/TRT

  • For fertility: short-course clomiphene 3–6 months with lifestyle-based.
  • On TRT: monitor hematocrit, estradiol, SHBG, PSA, BP; address sleep apnea.
  • Optimize resistance training and recovery.

Thyroid optimization

  • If reverse T3 is high and symptoms persist, investigate inflammation and gut.
  • Consider T3 add-on or desiccated thyroid with careful monitoring.
  • Support with selenium, zinc, iron, and vitamin D; improve sleep and stress load.

Estriol/estradiol

  • Use local estradiol or estriol for urogenital symptoms; monitor if combining with estradiol systemically.
  • Expect estriol alone to be too weak for hot flashes.

Closing Perspective

Modern endocrine care thrives at the intersection of precise physiology and whole-person mechanics. When we calibrate hormones thoughtfully, correct nutrient deficits, and restore movement and autonomic balance, patients experience durable improvements in energy, cognition, metabolism, and quality of life. Integrative chiropractic care is not an add-on; it is a force multiplier—aligning the nervous system and musculoskeletal frame to receive and respond to biochemical therapies. My day-to-day observations mirror the literature: when we treat the individual and the system, outcomes follow.


References

Insights for Androgen Hormone Optimization & Chronic Diseases

Discover how androgen hormone optimization for chronic diseases affects your body and find solutions for improved health.

Abstract

As a clinician, educator, and researcher, I work at the intersection of physiology and patient outcomes. In this educational post, I, Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, present a comprehensive, first-person synthesis of how balanced androgen and estrogen signaling shapes brain function, bone remodeling, cardiovascular and metabolic resilience, sexual health, and cancer risk. I explain the androgen receptor (AR) and estrogen receptor (ER) biology that underpins modern practice, why aromatization to estradiol and 5α-reduction to dihydrotestosterone (DHT) are essential—not side pathways—and how the prostate saturation model reframes longstanding myths about testosterone and prostate cancer. I detail how I evaluate and optimize testosterone replacement therapy (TRT) for men and physiologic androgen support for women, including when to prefer transdermal estradiol, how to monitor free testosterone and sex hormone–binding globulin (SHBG), and how to protect safety by tracking hematocrit, PSA, and metabolic markers. I also address nuanced areas such as opioid-induced androgen deficiency, androgen support in women with elevated SHBG, and receptor-informed reasoning for breast and prostate cancer risk. Throughout, I highlight peer-reviewed evidence from leading researchers and integrate clinical observations from my work at chiromed.com and my professional updates at LinkedIn, to empower patients and clinicians to make informed, physiology-respecting decisions.

Hormone Physiology 101: Why Androgens and Estrogens Work Better Together

In every tissue I examine—brain, bone, heart, muscle, skin—the conversation between androgens and estrogens is continuous and collaborative. Testosterone occupies a central node in this conversation because it acts:
By directly activating the androgen receptor (AR) to drive protein synthesis, erythropoiesis, endothelial function, and neuromodulation.
It aromatizes to estradiol (E2), which is indispensable for bone mineral density, synaptic plasticity, and vascular flexibility.
By 5α-reducing to dihydrotestosterone (DHT), a higher-affinity AR ligand that supports sexual function, mood, and neurovascular stability.
These conversions are not waste; they are physiological amplifiers that tune responses by tissue. When clinicians indiscriminately block aromatase or 5α-reductase, patients can lose essential downstream signaling. I frequently see men who arrive on a 5α-reductase inhibitor for hair loss and an SSRI for premature ejaculation with near-zero DHT and low E2. The clinical picture—profound loss of libido, erectile dysfunction, emotional blunting—matches what the physiology predicts: too little AR and ER engagement. Respecting these pathways and restoring balanced AR/E2 signaling is often the turning point.
Clinical takeaway
Bold principle: Do not reflexively block physiological androgen conversions; treat the person, not just the lab number.
References: Bhasin et al., 2018

The Case for Testosterone Optimization in Men and Women

When hypogonadism is accurately diagnosed and treatment is monitored, physiological TRT is associated with meaningful improvements across systems:
Cardiovascular and vascular function
Improved endothelial nitric oxide signaling, decreased inflammatory tone, and improved body composition correlate with neutral-to-favorable cardiovascular outcomes in hypogonadal men whose testosterone is brought back to physiologic ranges (Bhasin et al., 2018; Corona et al., 2018; Khera et al., 2020).
Metabolic health
Androgens enhance insulin signaling and reduce visceral adiposity; TRT can improve glycemic control and metabolic syndrome features in androgen-deficient men (Corona et al., 2018).
Mood and cognition
AR signaling influences dopaminergic and serotonergic networks. Restoring deficient testosterone often improves vitality and depressive symptoms (Walther et al., 2019).
Sexual function
Physiologic TRT improves desire and erectile quality through both AR and nitric oxide pathways.
Bone and muscle
Estradiol derived from testosterone is essential for bone remodeling, while AR signaling drives muscle protein synthesis and strength.
For women, carefully dosed physiologic testosterone can improve desire, arousal, energy, and cognition when free testosterone is low—particularly when SHBG is high and blunts receptor access. While FDA-approved options for women are limited in the U.S., off-label, evidence-based protocols are supported by position statements and RCT meta-analyses (Davis et al., 2019; Islam et al., 2019).
References: Bhasin et al., 2018; Corona et al., 2018; Walther et al., 2019; Davis et al., 2019; Islam et al., 2019; Khera et al., 2020

Prostate Health and the Saturation Model: Reframing an Old Myth

For decades, clinical teaching suggested testosterone “fuels” prostate cancer. Modern evidence, led by Dr. Abraham Morgentaler and colleagues, paints a more precise picture:
Saturation model
Prostate ARs saturate at relatively modest serum testosterone concentrations. Above this threshold, additional testosterone does not linearly increase intraprostatic signaling (Morgentaler & Traish, 2009).
Practical point: Men with low-to-mid “normal” serum T typically have near-maximal intraprostatic AR occupancy; moving from low to mid-physiologic ranges does not predict proportional PSA rises or cancer risk. If PSA rises significantly on TRT, investigate prostatitis, occult malignancy, or other drivers—do not simply assume “testosterone did it.”
Low testosterone as a risk marker
Observational data associate lower baseline testosterone with higher-grade disease at diagnosis and worse prognostic indicators (Morgentaler, 2006; Isbarn et al., 2009).
In properly selected men treated for localized prostate cancer with no evidence of disease, carefully monitored TRT has not shown increased recurrence in multiple series (Pastuszak et al., 2013).
My practice experience
Men with symptomatic hypogonadism and benign prostatic hyperplasia (BPH), when cancer-negative, deserve a nuanced TRT discussion. In my clinic, treating physiologic targets rarely worsens lower urinary tract symptoms. If symptoms worsen, I look for other causes.
References: Morgentaler & Traish, 2009; Morgentaler, 2006; Pastuszak et al., 2013

Androgen Deprivation Therapy: Cognitive and Cardiometabolic Costs

Androgen deprivation therapy (ADT) remains important for advanced or high-risk prostate cancer. However, the systemic costs are not trivial:
Cognition
Observational studies link ADT with higher risks of cognitive decline and Alzheimer’s disease (Nead et al., 2017).
Cardiometabolic health
ADT worsens insulin resistance, increases visceral adiposity, depresses endothelial nitric oxide, and increases cardiovascular events (Zhao et al., 2014).
Bone and muscle
Accelerated bone loss and sarcopenia occur in the absence of androgen and estradiol signaling.
Where oncologically feasible, I favor organ-directed strategies without prolonged systemic hormone suppression, particularly in men with high cardiometabolic risk. When ADT is required, we proactively mitigate risk: progressive resistance training, vitamin D and calcium, bone-protective agents when indicated, nutrition, sleep optimization, and close cardiovascular monitoring.
References: Nead et al., 2017; Zhao et al., 2014

Normal vs Optimal: Why Reference Ranges Are Not Targets

A reference range reflects where 95% of the sampled population falls; it does not define the zone of optimal health. For hormones that decline with age, “normal” skews lower as the population ages and accrues comorbidities.
Evidence signal
Meta-analytic and cohort data link low-quantile testosterone in men with significantly higher risk of all-cause dementia and Alzheimer’s disease—even when values sit within “normal” lab ranges (Chu et al., 2020).
Clinical principle
I aim for optimal physiological targets based on outcomes—not merely clearing the lower bound of normal. For symptomatic men, that often means the upper half of physiologic ranges, provided safety metrics remain favorable.
References: Chu et al., 2020

Women, Androgens, and SHBG: Treating What Cells “Feel,” Not Just What Labs Print

Women rely on ovarian and adrenal androgens for sexual desire, arousal, bone and muscle integrity, and cognitive drive. The clinical challenge I see daily is high SHBG—especially with oral estrogens, certain medications (including SSRIs), thyroid shifts, or liver changes—binding testosterone and shrinking the free/bioavailable fraction that actually reaches receptors.
Why women feel “not themselves” with “normal” labs
A “normal” total testosterone level with high SHBG can mean low free testosterone at the receptor level. Symptoms—low desire, fatigue, cognitive fog, diminished exercise capacity—reflect a genuine female androgen deficiency despite a normal total.
My approach
I prioritize free testosterone (equilibrium dialysis or validated calculation) and SHBG, not just total testosterone, and titrate to physiologic free levels that resolve symptoms while monitoring for side effects.
Pellets and transdermal therapy
For select women, bioidentical testosterone pellets provide steady pharmacokinetics that overcome high SHBG, improve adherence, and stabilize symptoms. For others, transdermal formulations enable flexible titration. The goal is normal receptor-level exposure, not elevated totals per se.
References: Davis et al., 2019; Islam et al., 2019; Parish et al., 2021

Breast, Prostate, and Receptor Biology: A Practical Lens for Risk

The most durable way to reason about cancer risk in hormone care is through receptor biology.
ER-alpha vs ER-beta
ER-alpha activation in breast tissue often increases BCL-2 (cell survival), while ER-beta tends to promote differentiation and apoptosis; estrone (E1), produced in adipose tissue, favors ER-alpha, especially in obesity (Jordan, 2014; Yasuda et al., 2020).
Androgen receptor in breast tissue
AR activation can counter ER-alpha-driven proliferation and reduce BCL-2 in the breast epithelium, providing a mechanistic basis for the anti-proliferative effects of androgens in certain contexts (D’Amato et al., 2020).
Progesterone vs progestins
Bioidentical progesterone has tissue-specific effects through PRA/PRB; some synthetic progestins (e.g., medroxyprogesterone acetate) interact adversely with AR and glucocorticoid receptors, contributing to discordant risk profiles (Sitruk-Ware & Plu-Bureau, 2018; Stute et al., 2016).
Practical implications in my clinic
In postmenopausal women with metabolic risk and estrone dominance, I emphasize weight loss, insulin sensitization, and, when indicated, transdermal estradiol plus bioidentical progesterone for endometrial protection. When women cannot use estrogen (e.g., certain oncology contexts), physiologic testosterone support—coordinated with oncology when applicable—can improve quality of life and adherence to aromatase inhibitors without evidence of increased breast cancer incidence at physiologic dosing.
References: Jordan, 2014; Yasuda et al., 2020; D’Amato et al., 2020; Sitruk-Ware & Plu-Bureau, 2018; Stute et al., 2016

Why Route Matters: Transdermal Estradiol and Vascular Safety

When I choose estrogen therapy, I often favor transdermal estradiol:
Avoid first-pass hepatic burden
Oral estrogens upregulate hepatic clotting factors and CRP and skew metabolite profiles, while transdermal routes deliver steady E2 with fewer hepatic effects (Canonico et al., 2007; Scarabin, 2018).
Brain and bone access
Transdermal estradiol supports consistent receptor engagement in the brain and bone, aligning with the goals of mood stabilization and bone remodeling.
To protect the endometrium in women with a uterus, I pair transdermal estradiol with micronized progesterone, which also assists sleep via GABAergic metabolites.
References: Canonico et al., 2007; Scarabin, 2018

Mechanisms That Explain Clinical Gains: Brain, Heart, Metabolism, Bone, and Muscle

Understanding the mechanism strengthens clinical decisions:
Brain
Estradiol and androgens modulate glutamatergic/GABAergic balance, upregulate BDNF, and reduce neuroinflammation; AR signaling enhances mesolimbic dopamine pathways relevant to motivation and mood (Albert et al., 2015; Kulkarni et al., 2022).
Cardiovascular system
Physiologic testosterone and estradiol increase eNOS activity and nitric oxide, reduce endothelin-1 and inflammatory adhesion molecules, and improve microvascular function (Vitali et al., 2014; Wu et al., 2018).
Metabolism
AR signaling increases insulin-stimulated GLUT4 translocation and PI3K/Akt activity in skeletal muscle, enhancing metabolic flexibility; normalization of T improves TG/HDL ratios and lowers hs-CRP in many patients (Kelly & Jones, 2015; Grossmann, 2011).
Bone and muscle
Estradiol is pivotal for osteoclast apoptosis and osteoblast survival; AR signaling via mTOR pathways supports muscle protein synthesis (Khosla & Monroe, 2018; Falahati-Nini et al., 2000).
References: Albert et al., 2015; Kulkarni et al., 2022; Vitali et al., 2014; Wu et al., 2018; Kelly & Jones, 2015; Grossmann, 2011; Khosla & Monroe, 2018; Falahati-Nini et al., 2000

My Stepwise Protocol: How I Evaluate, Treat, and Monitor Hormone Health

I align therapy with physiology and outcomes, not just numbers:
Baseline evaluation
Symptoms: libido, sexual function, energy, sleep, mood, cognitive clarity; in men, lower urinary tract symptoms; in women, menopausal status and vasomotor load.
Labs: total and free testosterone, SHBG, estradiol (sensitive assay in men; appropriate assay in women), LH/FSH, prolactin, thyroid panel, fasting insulin/glucose or A1c, lipid profile, CBC (hematocrit), CMP, PSA (men), vitamin D.
Reasoning: Distinguish primary vs secondary hypogonadism, quantify aromatization potential (e.g., via SHBG, adiposity), and set safety baselines.
Formulation and dosing
Men: weekly testosterone cypionate injections to minimize peak levels; transdermal gels/creams or pellets, based on lifestyle and response.
Women: low-dose transdermal or pellet therapy when indicated; anchor dosing on free testosterone and response.
Reasoning: Match pharmacokinetics to patient needs; avoid supraphysiologic peaks that increase the risk of side effects.
Preserve physiological conversions
Avoid routine 5α-reductase blockade; monitor estradiol levels and support weight loss and resistance training to balance aromatization; modulate aromatase only cautiously when clinically necessary.
Reasoning: DHT and E2 are beneficial at physiologic levels; suppression can worsen joints, libido, and mood.
Monitoring cadence
4–8 weeks post-initiation or dose change: trough testosterone, estradiol, hematocrit, PSA (men), blood pressure, symptoms.
3–6 months: reassess labs and adjust to align symptom relief with optimal ranges.
Stable phase: semiannual to annual follow-up.
Safety management
Hematocrit: adjust dose/route; split dosing; treat sleep apnea; consider therapeutic phlebotomy if appropriate.
PSA: Investigate unexpected rises with urology; do not reflexively blame TRT.
Lipids/glucose: manage with lifestyle and medications when needed.
References: Bhasin et al., 2018

Depression, Drive, and the Androgen–Mood Connection

The neurobiology is clear: ARs in prefrontal and limbic networks cross-talk with dopamine and serotonin. In practice, low androgen states often present with low drive, anhedonia, irritability, and sleep disruption. Randomized and observational studies show that restoring physiologic testosterone in androgen-deficient adults improves depressive symptoms and vitality (Walther et al., 2019). In my clinic, when hormones are corrected, patients often re-engage more effectively with psychotherapy and lifestyle change—because biological capacity underpins behavior.
References: Walther et al., 2019

Clinical Cases I See Repeatedly

Young man, post 5α-reductase inhibitor
Presentation: low libido, ED, tearfulness; labs show mid-range total T, near-zero DHT, and low estradiol.
Plan: stop unnecessary blockade, initiate low-dose weekly TRT, restore DHT and E2 levels to normal ranges; add resistance training and sleep optimization.
Outcome: libido, erections, and mood rebound within 8–12 weeks.
Midlife man with metabolic syndrome
Presentation: low-normal T, obesity, prediabetes, cognitive “fog.”
Plan: weekly TRT, nutrition, progressive resistance training; dose-splitting to control hematocrit.
Outcome: improved A1c, reduced waist, sharper concentration, better sleep.
Perimenopausal woman with high SHBG
Presentation: low desire, poor recovery, brain fog; normal total T with elevated SHBG and low free T.
Plan: transdermal or pellet testosterone titrated to physiologic free T; optimize estradiol and progesterone as indicated.
Outcome: improved focus, spontaneous desire, and stronger training performance within 6–8 weeks.

Opioid-Induced Androgen Deficiency: Breaking the Pain Cycle

Chronic opioids suppress the hypothalamic–pituitary–gonadal axis, leading to opioid-induced androgen deficiency (OPIAD). The result is higher pain perception, sarcopenia, sleep fragmentation, and depression—driving higher opioid doses and further suppression.
My protocol
Screen with morning total and free testosterone, SHBG, LH/FSH, prolactin, thyroid, vitamin D, and iron studies.
Replace androgens when deficiency is documented; coordinate pain management; implement resistance training, sleep therapy, and non-opioid analgesic strategies.
Outcome: improved pain thresholds, physical function, and capacity to reduce opioid reliance (Daniell, 2006; Rubinstein & Carpenter, 2014).
References: Daniell, 2006; Rubinstein & Carpenter, 2014

Bone Health: Integrating Estradiol, Testosterone, Vitamin D3, and K2

I pair hormone optimization with vitamin D3 and vitamin K2 in patients at risk for bone loss.
Mechanisms
Estradiol shortens osteoclast lifespan, supports osteoblast survival; testosterone stimulates osteoblast differentiation and periosteal formation and aromatizes locally to estradiol in bone; vitamin D3 improves calcium absorption; vitamin K2 gamma-carboxylates osteocalcin for proper mineralization (Khosla & Monroe, 2018; Falahati-Nini et al., 2000; Schwalfenberg, 2017).
Clinical practice
I order DXA every 2–3 years, depending on risk and therapy changes; I often see stabilization or improvement when patients adhere to transdermal estradiol (as indicated), physiologic testosterone (in men and select women), D3/K2, and resistance training.
References: Khosla & Monroe, 2018; Falahati-Nini et al., 2000; Schwalfenberg, 2017; Black & Rosen, 2016

Cardiovascular Safety: Separating Physiologic TRT From Anabolic Abuse

Physiologic replacement of testosterone in hypogonadal patients differs fundamentally from supraphysiologic anabolic steroid use. The literature demonstrates neutral-to-favorable cardiovascular signals when therapy is kept within physiologic ranges, comorbidities are managed, and hematocrit, blood pressure, and lipids are monitored (Bhasin et al., 2018; Corona et al., 2018). Mechanistically, eNOS upregulation, anti-inflammatory shifts, and improved body composition explain observed benefits (Vitali et al., 2014).
References: Bhasin et al., 2018; Corona et al., 2018; Vitali et al., 2014

Ovarian Conservation, Longevity, and Androgens

Cohort data show that ovarian conservation at hysterectomy (when ovaries are normal and risk is low) is associated with lower all-cause and cardiovascular mortality (Parker et al., 2009). I counsel patients on the continuing production of androgens by postmenopausal ovaries and the downstream benefits for muscle, bone, endothelial function, and mood. When ovaries are removed, compensatory androgen strategies may be appropriate under careful evaluation.
References: Parker et al., 2009

Putting It All Together: Decision Pathway for Patients and Clinicians

Step 1: Listen for pattern recognition
Do symptoms cluster in brain, bone, metabolic, sexual, or vascular domains, suggesting androgen/estrogen deficiency?
Step 2: Establish a comprehensive baseline
Include free testosterone, SHBG, and safety labs; interpret beyond”normal ranges.”
Step 3: Align on goals and context
Discuss fertility plans (TRT can suppress spermatogenesis), prostate status, oncologic history, cardiometabolic risk, and personal priorities.
Step 4: Choose routes that respect physiology
Favor steady kinetics (weekly injections, transdermal, pellets as appropriate). Preserve necessary conversions to E2 and DHT; titrate to symptom relief within physiologic bands.
Step 5: Monitor and adapt
Use symptom instruments, labs, and imaging (DXA) to ensure benefits while maintaining safety.

My Clinic, Observations, and Ongoing Education

At my integrative clinics, the most durable outcomes occur when hormone optimization is paired with strength training, nutrition, sleep, and stress management. We quantify progress with symptom scores, labs, and imaging. When mood or cognition remains impaired despite normalized sex steroids, I look deeper: thyroid, sleep apnea, iron and B12, inflammation, or primary mood disorders warrant coordinated care.
Learn more about my clinical approach and case insights:
Clinical education and resources: https://chiromed.com/
Professional updates: https://www.linkedin.com/in/dralexjimenez/

Key Myths Revisited

Myth: Testosterone causes prostate cancer.
Evidence-based view: The saturation model and modern cohorts do not support a causal relationship; low testosterone is associated with more severe pathology at diagnosis (Morgentaler & Traish, 2009; Morgentaler, 2006).
Myth: Normal lab range equals normal health.
Evidence-based view: Reference ranges reflect populations, not optimal outcomes. Aim for outcome-informed targets (Chu et al., 2020).
Myth: DHT is always harmful.
Evidence-based view: DHT is critical for sexual and neurovascular function at physiologic levels; problems arise with dysregulated or tissue-specific excess.
Myth: TRT equals anabolic steroid abuse.
Evidence-based view: Physiologic TRT differs in pharmacology, dose, and risk from supraphysiologic steroid misuse (Bhasin et al., 2018).

Final Perspective

Hormones are not luxury biochemistry; they are foundational signals keeping neurovascular, musculoskeletal, and metabolic networks synchronized. The most reliable outcomes I see in practice occur when we:
Respect physiology and avoid reflexively blocking androgen conversions.
Aim for optimal, outcomes-based targets within physiologic ranges.
Monitor proactively with symptom instruments and safety labs.
Educate patients clearly and invite them into shared decision-making.
If you would like to explore a personalized, evidence-based hormone evaluation with careful monitoring and outcome tracking, my team and I are available through our clinical resources and professional channels listed above. This educational post was created on 2026-01-16 09:40:23 and reflects contemporary research and clinical observations as summarized by me.

References



SEO tags: testosterone therapy, androgen receptors, dihydrotestosterone DHT, estradiol aromatization, prostate saturation model, hypogonadism treatment, women and androgens, cardiovascular risk testosterone, dementia risk testosterone, ADT side effects, functional medicine hormones, TRT monitoring protocol, optimal vs normal hormone ranges, estradiol transdermal, progesterone sleep, insulin sensitivity hormones, bone density vitamin D3 K2, endothelial function nitric oxide, thyroid metabolism, opioid-induced androgen deficiency, SHBG free testosterone, bioidentical pellets, breast cancer and testosterone, evidence-based hormone therapy, Dr. Alexander Jimenez